PortalPublikationenThrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID...

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination

Standard

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination. / Hosseinzadeh, Rezvan; Barary, Mohammad; Mehdinezhad, Hamed; Sio, Terence T; Langer, Florian; Khosravi, Sahar.

in: RES PRACT THROMB HAE, Jahrgang 6, Nr. 4, e12750, 05.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hosseinzadeh, R, Barary, M, Mehdinezhad, H, Sio, TT, Langer, F & Khosravi, S 2022, 'Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination', RES PRACT THROMB HAE, Jg. 6, Nr. 4, e12750. https://doi.org/10.1002/rth2.12750

APA

Hosseinzadeh, R., Barary, M., Mehdinezhad, H., Sio, T. T., Langer, F., & Khosravi, S. (2022). Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination. RES PRACT THROMB HAE, 6(4), [e12750]. https://doi.org/10.1002/rth2.12750

Vancouver

Hosseinzadeh R, Barary M, Mehdinezhad H, Sio TT, Langer F, Khosravi S. Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination. RES PRACT THROMB HAE. 2022 Mai;6(4). e12750. https://doi.org/10.1002/rth2.12750

Bibtex

@article{3dde26d9880a41af98f6915d7268aed1,
title = "Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination",
abstract = "Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.Key Clinical Question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.Clinical Approach and Conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.",
author = "Rezvan Hosseinzadeh and Mohammad Barary and Hamed Mehdinezhad and Sio, {Terence T} and Florian Langer and Sahar Khosravi",
note = "{\textcopyright} 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).",
year = "2022",
month = may,
doi = "10.1002/rth2.12750",
language = "English",
volume = "6",
journal = "RES PRACT THROMB HAE",
issn = "2475-0379",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination

AU - Hosseinzadeh, Rezvan

AU - Barary, Mohammad

AU - Mehdinezhad, Hamed

AU - Sio, Terence T

AU - Langer, Florian

AU - Khosravi, Sahar

N1 - © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).

PY - 2022/5

Y1 - 2022/5

N2 - Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.Key Clinical Question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.Clinical Approach and Conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.

AB - Background: Severe side effects after vaccination with coronavirus disease 2019 (COVID-19) vaccines are rare but can be fatal. To date, vaccine-induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID-19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine.Key Clinical Question: The Key Clinical Question was to determine whether inactivated COVID-19 vaccines could induce VITT and how to diagnose and treat such cases.Clinical Approach and Conclusions: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti-heparin-platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high-dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.

U2 - 10.1002/rth2.12750

DO - 10.1002/rth2.12750

M3 - SCORING: Journal article

C2 - 35769629

VL - 6

JO - RES PRACT THROMB HAE

JF - RES PRACT THROMB HAE

SN - 2475-0379

IS - 4

M1 - e12750

ER -